‘Excited about the pipeline’: Why Wilson says the CSL share price is in the buy zone right now

The CSL Limited (ASX: CSL) share price has climbed 3% in the past month, but could it go higher?

CSL shares fell 0.37% today to $295.64. In comparison, the S&P/ASX 200 Index (ASX: XJO) leapt 0.07% on Monday.

So what is the outlook for the CSL share price?

Could the CSL share price jump higher?

CSL is a global biotech giant working on vaccines and plasma products to treat diseases.

Recently, Wilson Asset Management experts have recommended shareholders buy CSL shares, as my Foolish colleague Tony reported.

Analyst Anna Milne highlighted the company’s Behring business has been “under earning for a number of years” and is “really starting to hit it’s strap”.

Further, Milne pushed the company’s plasma and vaccine advantages and how that would help the company. Commenting on CSL’s Seqirus influenza business, she said:

Seqiris is the vaccine business… it’s been a pretty horrendous flu season Down Under and we think that’ll probably translate to the same in the northern hemisphere.

In addition, Milne commented on the company’s Vifor Pharma acquisition:

The Vifor transaction, which has been delayed, but management is still very confident that it’s going to close and we’re really excited about the pipeline of drugs there.

So CSL’s a buy.

On 2 August, CSL revealed to the market it has received all the regulatory clearance required to finalise the acquisition of Vifor Pharma.

Completion of this acquisition is due tomorrow, on 9 August.

CSL is due to report earnings in FY22 on Wednesday next week.

CSL share price snapshot

The CSL share price has slipped 0.78% in the past year, while it has gained climbed 1.7% year to date. For perspective, the ASX 200 has shed nearly 7% in a year.

CSL has a market capitalisation of more than $142 billion based on the current share price.

The post ‘Excited about the pipeline’: Why Wilson says the CSL share price is in the buy zone right now appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 3 ASX 200 shares to buy for a post-COVID resurgence: experts
• Up 8% in July, is there more upside in the CSL share price this earnings season?
• Why Citi just became even more bullish on the CSL share price
• What’s going on with the CSL share price on Tuesday?
• 5 things to do during ASX results season

Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/7WBhDnO